Evidence map›Paper›PMID 34944416›Full record

ReviewBiomolecules2021

The ANXA2/S100A10 Complex-Regulation of the Oncogenic Plasminogen Receptor.

Alamelu G Bharadwaj, Emma Kempster, David M Waisman

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Cancer biology & therapy · 2025
    Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Alamelu G BharadwajDepartments of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada.
Emma KempsterDepartments of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada.
David M WaismanDepartments of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada.
Dalhousie University · CA

Funding

CIHR 162283
6 · The paper itself

Abstract

The generation of the serine protease plasmin is initiated by the binding of its zymogenic precursor, plasminogen, to cell surface receptors. The proteolytic activity of plasmin, generated at the cell surface, plays a crucial role in several physiological processes, including fibrinolysis, angiogenesis, wound healing, and the invasion of cells through both the basement membrane and extracellular matrix. The seminal observation by Albert Fischer that cancer cells, but not normal cells in culture, produce large amounts of plasmin formed the basis of current-day observations that plasmin generation can be hijacked by cancer cells to allow tumor development, progression, and metastasis. Thus, the cell surface plasminogen-binding receptor proteins are critical to generating plasmin proteolytic activity at the cell surface. This review focuses on one of the twelve well-described plasminogen receptors, S100A10, which, when in complex with its regulatory partner, annexin A2 (ANXA2), forms the ANXA2/S100A10 heterotetrameric complex referred to as AIIt. We present the theme that AIIt is the quintessential cellular plasminogen receptor since it regulates the formation and the destruction of plasmin. We also introduce the term

Indexed as

Annexin A2Biomarkers, TumorEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMultiprotein ComplexesNeoplasmsPrognosisS100 Calcium Binding Protein A10S100 ProteinsAnnexin A2ANXA2 protein, humanBiomarkers, TumorMultiprotein ComplexesS100 Calcium Binding Protein A10S100 Proteinsannexin A2metastasisoncogeneplasminplasminogenS100A10

Identifiers

PMID34944416
PMCPMC8698604
OpenAlexW3215712758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.